205 related articles for article (PubMed ID: 18808404)
1. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation.
Zarkhin V; Li L; Kambham N; Sigdel T; Salvatierra O; Sarwal MM
Am J Transplant; 2008 Dec; 8(12):2607-17. PubMed ID: 18808404
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in pediatric renal transplantation: a treatment for allograft rejection with B-cell infiltrates?
Zand MS
Am J Transplant; 2008 Dec; 8(12):2489-90. PubMed ID: 19032220
[No Abstract] [Full Text] [Related]
3. Pharmacodynamics of rituximab in kidney allotransplantation.
Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
Am J Transplant; 2006 Oct; 6(10):2418-28. PubMed ID: 16925569
[TBL] [Abstract][Full Text] [Related]
4. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab.
Lehnhardt A; Mengel M; Pape L; Ehrich JH; Offner G; Strehlau J
Am J Transplant; 2006 Apr; 6(4):847-51. PubMed ID: 16539643
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
6. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.
Tydén G; Genberg H; Tollemar J; Ekberg H; Persson NH; Tufveson G; Wadström J; Gäbel M; Mjörnstedt L
Transplantation; 2009 May; 87(9):1325-9. PubMed ID: 19424032
[TBL] [Abstract][Full Text] [Related]
7. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
8. Early and late humoral rejection: a clinicopathologic entity in two times.
Péfaur J; Díaz P; Panace R; Salinas P; Fiabane A; Quinteros N; Chea R; Naranjo E; Wurgaft A; Beltran E; Elgueta S; Wegmann ME; Gajardo JG; Contreras L
Transplant Proc; 2008 Nov; 40(9):3229-36. PubMed ID: 19010241
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
[TBL] [Abstract][Full Text] [Related]
10. Acute cellular rejection with CD20-positive lymphoid clusters in kidney transplant patients following lymphocyte depletion.
Kayler LK; Lakkis FG; Morgan C; Basu A; Blisard D; Tan HP; McCauley J; Wu C; Shapiro R; Randhawa PS
Am J Transplant; 2007 Apr; 7(4):949-54. PubMed ID: 17331114
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in the treatment of acute cellular rejection of renal allograft with CD20-positive clusters in the infiltrate.
Vega J; Goecke H; Carrasco A; Escobar C; Escobar M; Espinosa R; Méndez G; de Los Ángeles Rodríguez M
Clin Exp Nephrol; 2011 Apr; 15(2):308-11. PubMed ID: 21152944
[TBL] [Abstract][Full Text] [Related]
12. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
[TBL] [Abstract][Full Text] [Related]
14. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in highly sensitized kidney transplant recipients.
Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
[TBL] [Abstract][Full Text] [Related]
16. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
17. Vienna experience of ABO-incompatible living-donor kidney transplantation.
Haidinger M; Schmaldienst S; Körmöczi G; Regele H; Soleiman A; Schwartz D; Derfler K; Steininger R; Mühlbacher F; Böhmig GA
Wien Klin Wochenschr; 2009; 121(7-8):247-55. PubMed ID: 19562281
[TBL] [Abstract][Full Text] [Related]
18. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG.
Vo AA; Toyoda M; Peng A; Bunnapradist S; Lukovsky M; Jordan SC
Am J Transplant; 2006 Oct; 6(10):2384-90. PubMed ID: 16869794
[TBL] [Abstract][Full Text] [Related]
19. Dense B cell infiltrates in paediatric renal transplant biopsies are predictive of allograft loss.
Muorah MR; Brogan PA; Sebire NJ; Trompeter RS; Marks SD
Pediatr Transplant; 2009 Mar; 13(2):217-22. PubMed ID: 18433412
[TBL] [Abstract][Full Text] [Related]
20. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.
Kamburova EG; Koenen HJ; Borgman KJ; ten Berge IJ; Joosten I; Hilbrands LB
Am J Transplant; 2013 Jun; 13(6):1503-11. PubMed ID: 23570303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
